Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2115-2120

  Gallagher, Diana C ^a   Bhatt, Rupal S ^b   Parikh, Samir M ^a   Patel, Parin ^a   Seery, Virginia ^b   McDermott, David F ^b   Atkins, Michael B ^b   Sukhatme, Vikas P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; INTERLEUKIN 2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL PERMEABILITY; CAPILLARY LEAK SYNDROME; CELL CULTURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOFLUORESCENCE; IN VITRO STUDY; KIDNEY CARCINOMA; MALE; MEDIATOR; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TUMOR REGRESSION; WEIGHT GAIN;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CARCINOMA, RENAL CELL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247486420     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2509     Document Type: Article

References (26)

1. Donskov F, Bennedsgaard KM, Hokland M, et al. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 2004;53:729-39.
2. Elias L, Hunt WC. A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy. Oncology 2001;61:91-101.
3. Bascon JU. Vascular leak syndrome: a troublesome side effect of immunotherapy. Immunopharmacology 1998;39:255-7.
4. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997;37:117-32.
5. Berthiaume Y, Boiteau P, Fick G, et al. Pulmonary edema during IL-2 therapy: combined effect of increased permeability and hydrostatic pressure. Am J Respir Crit Care Med 1995;152:329-35.
6. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2, J Clin Oncol 1989;7:7-20.
7. Cotran RS, Pober JS, Gimbrone MA, et al. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988;140:1883-8.
8. Yi ES, Ulich TR. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol 1992;140:659-63.
9. Li J, Gyorffy S, Lee S, Kwok CS. Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro. Inflammation 1996;20:361-72.
10. Ohkubo C, Bigos D, Jain RK. Interleukin 2 induced leukocyte adhesion to the normal and tumor microvascular endothelium in vivo and its inhibition by dextran sulfate: implications for vascular leak syndrome. Cancer Res 1991;51:1561-3.
11. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res 1988;48:5528-32.
12. Assier E, Jullien V, Lefort J, et al. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J Immunol 2004;172:7661-8.
13. Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-2 - induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2 - associated side effects. Blood 1990;76:1933-40.
14. Du Bois JS, Trehu EG, Mier JW, et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997;15:1052-62.
15. McDermott DF, Trehu EG, Mier JW, et al. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin Cancer Res 1998;4:1203-13.
16. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
17. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
18. Parikh SM, Mammoto T, Schultz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006;3:356-70.
19. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
20. McDonald DM, Thurston G, Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 1999;6:7-22.
21. McDonald DM. Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli. Am J Physiol 1994;266:L61-83.
22. Jacobson JR, Dudek SM, Singleton PA, Kolosova IA, Verin AD, Garcia JG. Endothelial cell barrier enhancement by ATP is mediated by the small GTPase Rac and cortactin. Am J Physiol Lung 2006;291:L289-95.
23. Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004;22:2371-8.
24. Lissoni P, Fumagalli L, Giani L, Rovelli F, Confalonieri G, Pescia S. Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations. Int J Biol Markers 1998;13:98-101.
25. Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res 2001;21:777-9.
26. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16.